RecruitingNCT04672733
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Sponsor
CSL Behring
Enrollment
100 participants
Start Date
Jun 10, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Adult patient (aged ≥18 years)
- Patients suffering from CIDP according to EAN/PNS 2021 criteria
- Planned switch from IVIg to Hizentra®
- Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
- Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion
- Patients who have a smartphone, a tablet or a computer
- Patients who have been informed verbally and in writing of the purposes of the study
Exclusion Criteria1
- Concomitant participation in an interventional clinical study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALHizentra
Solution for injection for subcutaneous use
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04672733
Related Trials
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662135 locations
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141115 locations
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT0692000447 locations
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579158 locations
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT073041543 locations